67 patents
Utility
Recognition Sequences for I-crei-derived Meganucleases and Uses Thereof
23 Mar 23
Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided.
Derek Jantz, James Jefferson Smith
Filed: 13 Jul 22
Utility
Engineered Meganucleases Having Specificity for Recognition Sequences In the Dystrophin Gene
16 Feb 23
The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene.
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Filed: 13 Sep 22
Utility
Optimized Engineered Meganucleases Having Specificity for a Recognition Sequence In the Hepatitis B Virus Genome
2 Feb 23
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within a Hepatitis B virus (HBV) genome.
Janel Lape, James Jefferson Smith
Filed: 4 Dec 20
Utility
Methods for Cancer Immunotherapy
2 Feb 23
The present invention encompasses methods of cancer immunotherapy, and particularly methods of allogeneic cellular immunotherapy, using particular lymphodepletion regimens in combination with particular populations of chimeric antigen receptor T cells expressing anti CD19 CAR PBCAR0191, anti CD20 CAR PBCAR20A or anti BCMA CAR PBCAR269A.
Bruce J. McCreedy, Jr., Derek Jantz, Aaron Martin, Daniel T. MacLeod
Filed: 3 Dec 20
Utility
CD20 Chimeric Antigen Receptors and Methods of Use for Immunotherapy
29 Dec 22
Provided herein are compositions and methods for the treatment of a disease, such as cancer, using a chimeric antigen receptor or genetically-modified cells comprising a chimeric antigen receptor having specificity for CD20.
Daniel T. MacLeod, Bruce J. McCreedy, JR., Aaron Martin
Filed: 30 Oct 20
Utility
Methods and Products for Producing Engineered Mammalian Cell Lines with Amplified Transgenes
20 Oct 22
Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 27 Jan 22
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
27 Sep 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 14 Mar 22
Utility
Compositions and Methods for Sequential Stacking of Nucleic Acid Sequences into a Genomic Locus
1 Sep 22
The present invention encompasses compositions and methods for the sequential stacking of donor nucleic acids into a single genomic locus within a cell to allow for the introduction of relatively long nucleic sequences.
Joann Hux, James Jefferson Smith
Filed: 24 Jul 20
Utility
Lymphodepletion Dosing Regimens for Cellular Immunotherapies
1 Sep 22
The present invention encompasses methods and compositions including genetically-modified cells expressing chimeric antigen receptors or exogenous T cell receptors, and pharmaceutical compositions thereof, for the treatment of cancer and other disorders and diseases.
Bruce J. McCreedy, Jr.
Filed: 20 Aug 20
Utility
Engineered Meganucleases Specific for Recognition Sequences In the Hepatitis B Virus Genome
4 Aug 22
The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV).
Derek Jantz, James Jefferson Smith
Filed: 4 Feb 22
Utility
Nucleic Acid Molecules Encoding an Engineered Antigen Receptor and an Inhibitory Nucleic Acid Molecule and Methods of Use Thereof
21 Jul 22
The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule.
Joann Hux, Aaron Martin, Derek Jantz, Clayton Beard
Filed: 4 Apr 22
Utility
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
12 Jul 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton
Filed: 26 Oct 21
Utility
Genetically-modified Immune Cells Comprising a Microrna-adapted Shrna (Shrnamir)
30 Jun 22
The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein.
Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
Filed: 14 Mar 22
Utility
Methods of Preparing Populations of Genetically-modified Immune Cells
30 Jun 22
The present disclosure provides methods for preparing a population of genetically-modified immune cells.
Tyler Goodwin, Aaron Martin, Melissa Samo
Filed: 3 Apr 20
Utility
Engineered Nucleases Useful for Treatment of Hemophilia a
23 Jun 22
The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene.
Derek Jantz, James Jefferson Smith, Victor Bartsevich, Clayton Beard, Michael G. Nicholson
Filed: 10 Mar 22
Utility
Optimization of Engineered Meganucleases for Recognition Sequences
23 Jun 22
The invention provides engineered meganucleases, derived from I-Crel, which have substitutions at particular positions that increase the activity of the nucleases for recognition sequences containing certain center sequences.
James Jefferson Smith, Hui Li
Filed: 7 May 20
Utility
Treatment of Retinitis Pigmentosa Using Engineered Meganucleases
12 May 22
Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele.
Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
Filed: 26 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
12 May 22
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyara Antony, Victor Bartsevich
Filed: 19 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Human T Cell Receptor Alpha Constant Region Gene
5 May 22
Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor.
Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
Filed: 19 Jan 22
Utility
Genetically-modified Cells Comprising a Modified Transferrin Gene
21 Apr 22
Disclosed herein are engineered nucleases that bind and cleave a recognition sequence within intron 1 of a transferrin gene, and methods of using such engineered nucleases to produce a genetically-modified eukaryotic cell comprising a modified transferrin gene.
Cassandra Gorsuch, Derek Jantz, James Jefferson Smith, Clayton Beard
Filed: 10 Jan 20